HER2-positive breast cancer

URI: https://gptkb.org/entity/HER2-positive_breast_cancer

GPTKB entity

Statements (54)

Predicate	Object
gptkbp:instanceOf	breast cancer subtype
gptkbp:clinicalTrialPhase	gptkb:CLEOPATRA_trial gptkb:EMILIA_trial gptkb:APHINITY_trial
gptkbp:diagnosedBy	gptkb:fluorescence_in_situ_hybridization immunohistochemistry
gptkbp:guidanceSystem	gptkb:NCCN_Guidelines gptkb:ASCO_Guidelines
gptkbp:hasBiomarker	HER2 protein overexpression
gptkbp:hasGeneAmplification	gptkb:ERBB2_gene
gptkbp:hasImaging	MRI PET scan ultrasound mammography
gptkbp:hasMetastasisSite	gptkb:cancer gptkb:bone brain liver
gptkbp:hasMolecularSubtype	gptkb:HER2-enriched gptkb:Luminal_B_(if_hormone_receptor_positive)
gptkbp:hasPrognosticMarker	gptkb:Ki-67 hormone receptor status
gptkbp:hasRadiationTherapy	adjuvant radiation
gptkbp:hasRecurrenceRisk	higher than HER2-negative breast cancer
gptkbp:hasStaging	gptkb:AJCC_TNM_system
gptkbp:hasSurgicalTreatment	gptkb:sentinel_lymph_node_biopsy gptkb:lumpectomy mastectomy
gptkbp:hasSurvivalRate	improved with targeted therapy
https://www.w3.org/2000/01/rdf-schema#label	HER2-positive breast cancer
gptkbp:incidence	15-20% of breast cancers
gptkbp:pathology	gptkb:invasive_lobular_carcinoma invasive ductal carcinoma (most common)
gptkbp:prognosis	more aggressive than HER2-negative breast cancer
gptkbp:riskFactor	gptkb:BRCA_gene_mutations age family history of breast cancer female sex
gptkbp:symptom	nipple discharge breast pain breast lump skin changes on breast
gptkbp:treatment	gptkb:ado-trastuzumab_emtansine gptkb:pertuzumab gptkb:trastuzumab gptkb:tucatinib gptkb:lapatinib gptkb:neratinib chemotherapy hormone therapy (if hormone receptor positive)
gptkbp:bfsParent	gptkb:Tukysa gptkb:Perjeta gptkb:APHINITY_trial
gptkbp:bfsLayer	6